SBIR Phase I: Microglassification: Dehydration Process for Protein Preservation

SBIR 第一阶段：微玻璃化：蛋白质保存的脱水过程

• 批准号: 0711914
• 负责人: David Gaul
• 金额: --
• 依托单位: Southeast TechInventures
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2007-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0711914&HistoricalAwards=false
• 关键词: SBIR; Phase; Microglassification; Dehydration; Process

This Small Business Innovation Research (SBIR) Phase I project develops a new method for preserving proteins by a Microglassification Process that controllably dehydrates proteins into microspheres. This process has the potential to stabilize proteins by removing water to a level that does not allow microorganisms to grow and without heating or cooling, effectively preserving the protein at room temperature. Proteins are an important class of molecules in medicine that are used to diagnose, prevent and treat diseases or to restore (maintain) normal body functions. This research tests some model proteins that are in common laboratory and/or clinical use, and this process will be compared to the current state-of-the-art process of freeze-drying. The goal of this feasibility study is to develop a new industrial process that avoids the damage of the freezedrying process yet preserves protein in a stabilized form at ambient temperature as a partially dehydrated microsphere product. After feasibility for the new Microglassification Process is shown, the company plans to develop methods for customizing it for use with specific molecules of commercial importance with corporate strategic partners who are manufacturers of biologicals.The company plans to develop a new molecule preservation business that can derive revenue via process licenses to customers involved in production as well generating revenue through process customization contracts. In addition, licenses could also be provided to selected equipment manufacturers who are designated as providers of process equipment as well as selected manufacturers of process supplies. The broader impact of this technology will be improved preservation of sensitive biologicals important to the bioscience and biomedical marketplace.

这个小企业创新研究（SBIR）第一阶段项目开发了一种通过微玻璃化过程保存蛋白质的新方法，该过程可控制地将蛋白质脱水成微球。这个过程有可能通过将水去除到不允许微生物生长的水平来稳定蛋白质，并且无需加热或冷却，有效地将蛋白质保存在室温下。蛋白质是医学中一类重要的分子，用于诊断，预防和治疗疾病或恢复（维持）正常的身体功能。这项研究测试了一些常见的实验室和/或临床使用的模型蛋白质，并将该过程与当前最先进的冷冻干燥过程进行比较。该可行性研究的目标是开发一种新的工业工艺，该工艺避免冷冻干燥工艺的破坏，同时在环境温度下将蛋白质以稳定的形式保存为部分脱水的微球产品。在证明了新微玻璃化工艺的可行性后，公司计划与生物制品制造商等企业战略合作伙伴一起开发用于具有商业重要性的特定分子的定制方法。公司计划开发新的分子保存业务，该业务可以通过向参与生产的客户提供工艺许可证获得收入，也可以通过工艺定制合同获得收入。此外，许可证还可提供给被指定为工艺设备供应商的选定设备制造商以及选定的工艺用品制造商。这项技术的更广泛影响将是改善对生物科学和生物医学市场重要的敏感生物制品的保存。